Ablynx appoints Hennie Hoogenboom as Chief Scientific Officer
Dr Hoogenboom brings nearly 20 years of experience in antibody discovery and engineering. During his career he has led numerous research initiatives involving the discovery of recombinant antibodies and other proteins for therapy in the fields of oncology and inflammation. Previous positions include Senior Vice President Discovery of Dyax Corp, founder of Target Quest BV, associate professor at the University of Maastricht and group leader at Cambridge Antibody Technology Ltd.
Dr Hoogenboom is an inventor on more than 20 patent families. He holds a PhD in antibody engineering and worked as a postdoctoral fellow with Sir Gregory Winter at the MRC, where he co-invented phage display technology for the isolation and engineering of human antibodies.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous